Clinical Trial

A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 20, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a phase 1，randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects
Trial Details
NCT Number NCT06980207
Lead Sponsor Luye Pharma Group Ltd.
Conditions Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
Enrollment 40 participants
Start Date 2025-05
Primary Completion 2025-10 (estimated)
Study Completion 2025-10 (estimated)
Updated on ClinicalTrials.gov 2025-05-20